Printer Friendly

Arcus Biosciences, Strata Oncology Forge Clinical Development Collaboration for Anti-PD-1 Antibody AB122.

M2 PHARMA-May 6, 2019-Arcus Biosciences, Strata Oncology Forge Clinical Development Collaboration for Anti-PD-1 Antibody AB122

(C)2019 M2 COMMUNICATIONS

- US-based biopharmaceutical company Arcus Biosciences, Inc. (NYSE: RCUS) and precision oncology company Strata Oncology, Inc have entered into a clinical development collaboration utilising Strata's precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus's clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy, the companies said.

As part of this partnership, Arcus will gain access to Strata's drug development platform, featuring leading capabilities to design and conduct transformative precision therapy studies.

AB122 will be evaluated across the Strata Precision Oncology Network of trial-ready health systems that employ the StrataNGSTM test to pre-screen advanced cancer populations to enable rapid and predictable enrollment of precision therapy trials.

The StrataNGS comprehensive tumor sequencing test is available to all advanced solid tumor patients through the Strata Trial (NCT03061305) to identify potential patients for precision therapy trials and to evaluate proprietary biomarkers that may predict response to therapies.

Using observational study data, Strata has demonstrated the potential predictive power of their proprietary biomarkers in multiple settings in which anti-PD-1 therapies are known to be effective.

Arcus and Strata hope to extend the use of some of these biomarkers to identify patients who may benefit from AB122 treatment in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy.

AB122 is currently being evaluated in an ongoing Phase 1 monotherapy dose-escalation trial in patients with advanced tumors and ongoing Phase 1/1b combination trials evaluating AB122 in combination with AB928, a potentially best-in-class adenosine receptor antagonist, and AB122 in combination with AB154, a novel anti-TIGIT antibody, in patients with advanced solid tumors.

Under the terms of the agreement, the parties will share development costs for the clinical collaboration.

Strata is eligible to receive USD 2.5m upon the achievement of a development milestone, as well as regulatory and commercial milestones and royalties on US net sales of AB122 in the biomarker-identified indication.

As further consideration, Arcus issued to Strata restricted shares of its common stock, which are subject to vesting based upon the achievement of regulatory milestones within certain timelines.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer immunotherapies.

Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b programme to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus's other product candidates.

Arcus's other programs include AB154, an anti-TIGIT antibody, which is being evaluated in a Phase 1 trial as monotherapy and in combination with AB122, and AB680, a small-molecule inhibitor of CD73, which is in a Phase 1 healthy volunteer study.

Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology.

Strata Oncology is a precision medicine company dedicated to transforming cancer care by systematizing precision oncology across a network of health systems and pharma companies.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 6, 2019
Words:529
Previous Article:Clovis Oncology Enters into Non-Dilutive Clinical Trial Financing with TPG Sixth Street Partners for up to USD 175m.
Next Article:TetraGenetics Names Taunton-Rigby, Baron and Grau to its Board of Directors.
Topics:

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |